|Articles|March 9, 2015

Column

  • The Column-03-09-2015
  • Volume 11
  • Issue 4

Lung Cancer Breath Test in Clinical Trial

The University of Leicester and Glenfield Hospital in Leicester, UK, are starting a clinical trial into a gas chromatography–field asymmetric ion mobility spectrometry sensor (Owlstone Nanotech Ltd.) for the detection of early-stage lung cancer.

The University of Leicester and Glenfield Hospital in Leicester, UK, are starting a clinical trial into a gas chromatography–field asymmetric ion mobility spectrometry sensor (Owlstone Nanotech Ltd.) for the detection of early-stage lung cancer. Dr Salman Siddiqui, a clinical senior lecturer and adult chest physician at the University of Leicester and Leicester’s Hospitals, said: “Lung cancer has one of the lowest 5-year survival rates of all cancers; however, early diagnosis can greatly improve a patient’s prognosis. Current diagnostic procedures such as a chest X-ray, CT scan, and bronchoscopy are costly and not without risks so the benefits of a non-invasive, cheaper alternative are clear.”

Articles in this issue

Newsletter

Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.